Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: A systematic review

AIDS Reviews

Volumn 12, Issue 2, 2010, Pages 67-75

  Gazzard, Brian ^a   Balkin, Andrew ^b   Hill, Andrew ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b AmberMed Ltd   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiretroviral drugs; Efavirenz; HIV; Neuropsychiatric complications

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE;

ABNORMAL DREAMING; ADVERSE OUTCOME; AGGRESSION; AGITATION; ANXIETY; ATTENTION DISTURBANCE; BLURRED VISION; CIRCUMORAL PARESTHESIA; CLUSTER HEADACHE; COMBINATION CHEMOTHERAPY; CONFUSION; CRANIAL NEUROPATHY; DEPRESSION; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FACIAL NERVE PARALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; IRRITABILITY; LETHARGY; LIBIDO DISORDER; MAJOR DEPRESSION; MEMORY DISORDER; MENTAL DISEASE; MIDDLE EAR PRESSURE; MONONEUROPATHY; MONOTHERAPY; MOOD DISORDER; NERVOUSNESS; NEUROLOGIC DISEASE; NIGHTMARE; PANIC; PHOBIA; PHOTOPHOBIA; POSTTRAUMATIC STRESS DISORDER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; US DIVISION OF AIDS SEVERITY GRADING SCALE; UVEITIS; VERTIGO; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; HOSPITALIZATION; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; STANDARD; UNITED STATES;

ANTI-HIV AGENTS; BENZOXAZINES; CLINICAL TRIALS AS TOPIC; HIV INFECTIONS; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPSYCHOLOGICAL TESTS; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 77956667215     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Justice A, McGinnis K, Atkinson J, et al. Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS. 2004;18:49-59.
2. Robertson K, Smurzynski M, Parsons T, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21:1915-21. (Pubitemid 47329768)
3. Bing E, Burnham A, Longshore D, et al Psychiatric disorders and drug use among HIV-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-8. (Pubitemid 32717795)
4. Rodkjaer L, Laursen T, Balle N, Sodemann M. Depression in patients with HIV is under-diagnosed: a cross-sectional study in Denmark. HIV Med. 2010;11:46-53.
5. Kacanek D, Jacobson D, Spiegelman D, Wanke C, Isaac R, Wilson I. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the nutrition fo healthy living study. J Acquir Immune Defic Syndr 2010;53:266-72.
6. Gonzalez-Lahoz A, Cikurel K, Simpson D. Selected neurologic complications of HIV and antiretroviral therapy The PRN Notebook. 2006;11:24-9.
7. Clifford D. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008;16:94-8.
8. Marra C, Zhao Y, Clifford D, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neuro-cognitive performance. AIDS. 2009;23:1359-66.
9. Simioni, S, Cavassini M, Annoni J, et al Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS [in press].
10. Munoz-Moreno J, Fumaz C, Ferrer M, et al. Neuropsychiatric symptoms associated with efavirenz. prevalence, correlates and management. A Neurobehavioral review AIDS Rev 2009;11:103-9.
11. Marzolini C, Telenti A, Decosterd L, Greub G, Biollaz J, Buclin T. Efavirenz levels can predict treatment failure and central nervous system side-effects in HIV-1-infected patients. AIDS. 2001;15:71-5. (Pubitemid 32055781)
12. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immun Defic Syndr. 2006;42:514-15. (Pubitemid 44050905)
13. Hammer S, Eron J, Reiss P, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel JAMA. 2008;300:555-70.
14. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe Available at. http://www. europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines12mai09.pdf [accessed May 2009].
15. Division of AIDS table for grading the severity of adult and pediatric adverse events [online]. Available from URL: http://www3.niaid.nih.gov/ LabsAndResources/resources/DAIDSClinRsrch/PDF/DAIDSAEGradingTable.pdf [accessed August 2009]
16. Staszewski S, Morales-Ramirez J, Tashima K, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73
17. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet. 2004;363:1253-63. (Pubitemid 38496486)
18. Squires K, Lazzarin A, Gatell J, et al Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV J Acquir Immune Defic Syndr. 2004;36:1011-19. (Pubitemid 38989366)
19. Riddler S, Haubrich R, Di Rienzo G, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106 (Pubitemid 351679596)
20. Cooper D, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection J Infect Dis. 2010;201:803-13
21. Cameron D, da Silva B, Arribas J, et al A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy J Infect Dis. 2008;198:234-40.
22. Lennox J, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet. 2009;374:796-806.
23. Lennox J, De Jesus E, Berger D, et al. raltegravir versus efavirenz regimens in treatment-naive hiv-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr [in press].
24. Pozniak A, Morales-Ramirez J, Katabira E, et al Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS. 2010;24:55-65.
25. De Jesus E, McCarty D, Farthing C, et al Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. Clin Infect Dis 2004;39:411-8. (Pubitemid 39050491)
26. Moyle G, De Jesus E, Cahn P, et al Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral naive HIV-infected patients. J Acquir Immune Defic Syndr. 2005;38:417-25. (Pubitemid 40381551)
27. De Jesus E, Herrera G, Teofilo E, et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral naïve HIV infected adults Clin Infect Dis. 2004;39:1038-46.
28. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201 (Pubitemid 38917996)
29. Gallant J, DeJesus E, Arribas J, et al. Tenofovir DF, emtricitabine and efavirenz vs zidovudine, lamivudine and efavirenz for HIV N Engl J Med. 2006;354:251-60.
30. th IAS Conference on HIV pathogenesis, treatment and prevention, Cape Town, South Africa, July 2009 [abstract LEPEB09].
31. Gulick R, Ribaudo H, Shikuma C, et al Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-61. (Pubitemid 38917251)
32. Gutierrez-Valencia A, Lopez-Cortes L, Vicana P, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events. Ann Intern Med 2009;151:1-9.
33. Fumaz C, Tuldra A, Ferrer A, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease-inhibitor-containing regimens. J Acquir Immune Defic Syndr. 2002;29:244-53. (Pubitemid 34208532)
34. Clifford D, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 2005;143:714-21.